Recently, there was a renewed interest in generating inhibitors to CTPS activity that selectively target CTPS1 for therapeutic use, to control immune responses (Martin et al, 2014, 2020; Lynch et al, 2021), cancer cell proliferation (Sun et al, 2022), and viral replication (Rao et al, 2021). This evidence concerns the gene CTPS1 and cancer.